GWLL
Goldenwell Biotech, Inc.3.0000
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
297.00MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Goldenwell Biotech narrowed its net loss to $5,220 in Q2 FY2025 ended June 30, 2025, from $49,920 a year earlier, thanks to $37,500 in service revenue offsetting $40,620 in general and administrative expenses, while sales ticked up to $139 from zero. For the first half, the net loss shrank to $39,596 from $80,897, with year-to-date revenue at $37,797 versus $297 last year (derived). Operating losses improved similarly, but interest expense of $2,100 widened the gap to net by 40%, mainly from that non-operating hit. Cash climbed to $76,507, bolstered by $27,104 in operating cash flow, yet related-party debt lingers at $95,588 amid a going-concern warning. No capex means free cash flow not disclosed in the 10-Q. Inventory sits at $174,788 from a related-party buy. Competition in nutraceuticals could squeeze thin margins further.
8-K
Auditor resigns over going concern
Goldenwell Biotech's auditor KCCW resigned on July 24, 2025, after issuing clean reports for 2023 and 2024 but flagging substantial going concern doubts. No disagreements arose on accounting or auditing matters. The board then appointed Michael Gillespie & Associates on August 14, 2025, a firm that previously handled a 2024 quarterly review. This switch underscores persistent financial pressures amid the biotech's operations.
10-Q
Q1 FY2025 results
Goldenwell Biotech posted a net loss of $34,377 for Q1 FY2025 ended March 31, 2025, up from $31,056 a year earlier, driven by higher general and administrative expenses of $32,277 versus $28,956, while revenue stayed at zero. Operating loss widened to $32,277 from $28,956 year-over-year, with the net figure differing mainly due to $2,100 in interest expense on long-term debt. Cash drained $32,277 to $17,127, reflecting operating outflows without financing inflows; free cash flow not disclosed in the 10-Q. Long-term liabilities stood at $189,250 net, including unsecured loans from Megalight Inc. due 2026-2027, alongside $95,588 owed to the CEO. Inventory held steady at $174,788. No revenue yet. Competition in nutraceuticals could delay product launches.
10-K
FY2024 results
Goldenwell Biotech eked out $139 in revenue for FY2024 ended December 31, 2024, a sharp 92% drop from $1,836 in 2023, with gross profit shrinking to $64 from $666 amid negligible sales of nutraceutical supplements. The full-year net loss widened to $131,498 from $117,361, driven by higher general and administrative expenses of $123,162, while interest on loans added $8,400 to the tally. No quarterly breakdowns are disclosed, but annual trends show decelerating momentum with inventory stagnant at $174,788 and cash dipping to $49,404. Liquidity relies on $119,250 in new third-party loans, pushing total debt to $189,250, yet no dividends or buybacks occurred. The company eyes $5M in funding to build manufacturing and ramp sales. Substantial doubt lingers over going-concern viability without fresh capital.
AAGH
America Great Health
0.00+0.00
BFNH
BioForce Nanosciences Holdings,
0.60+0.07
BHST
BioHarvest Sciences Inc.
5.50+0.30
CYAN
Cyanotech Corp.
0.40+0.01
GLUC
Glucose Health, Inc.
0.14+0.00
HIGR
HI-GREAT GROUP HOLDING COMPANY
0.23+0.00
LFVN
Lifevantage Corporation
6.33-0.12
NAGE
Niagen Bioscience, Inc.
6.34-0.03
NPRFF
NEPRA FOODS INC.
0.10+0.00
SMPL
The Simply Good Foods Company
19.11-0.19